A phase 1, open-label, dose escalation study of ANG1005 in patients with malignant glioma.

Trial Profile

A phase 1, open-label, dose escalation study of ANG1005 in patients with malignant glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Paclitaxel trevatide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Sponsors AngioChem
  • Most Recent Events

    • 14 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
    • 09 Jun 2010 Added actual pt number 63.
    • 09 Jun 2010 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top